Comparative Pharmacology
Head-to-head clinical analysis: ATMEKSI versus SILDENAFIL CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATMEKSI versus SILDENAFIL CITRATE.
ATMEKSI vs SILDENAFIL CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Sildenafil citrate inhibits phosphodiesterase type 5 (PDE5) in the corpus cavernosum, increasing cGMP levels and enhancing nitric oxide-mediated smooth muscle relaxation, leading to penile erection. It also inhibits PDE5 in pulmonary vasculature, causing vasodilation and reducing pulmonary artery pressure.
1.5 mg/kg IV every 4 weeks
50 mg orally as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability; maximum dosing frequency once per day.
None Documented
None Documented
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Terminal elimination half-life 3-5 hours; clinical effect duration shorter due to distribution.
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Approximately 80% fecal, 13% renal as metabolites; <1% unchanged in urine.
Category C
Category A/B
PDE5 Inhibitor
PDE5 Inhibitor